NEIM-08 A PHASE II STUDY OF MULTIPARAMETRIC MR-GUIDED HIGH DOSE ADAPTIVE RADIOTHERAPY WITH CONCURRENT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

ABSTRACT: Abstract

BACKGROUND

Biologically-informed radiotherapy (RT) targeting an adversely prognostic hypercellular/hyperperfused imaging phenotype in patients with newly diagnosed glioblastoma (GBM) may improve outcomes by identifying emerging regions of treatment resistance associated with survival (OS), and is under investigation as a target for individualized, adaptive RT in an ongoing Phase II trial (NCT04574856).

METHODS

In this single-arm study, patients with newly diagnosed GBM following resection undergo dose-intensified chemoRT targeting the residual hypercellular (TVHCV, mean contralateral normal brain+2SD) and hyperperfused tumor volume (TVCBV, contralateral normal frontal grey matter+1SD) identified using high b-value diffusion-weighted and dynamic contrast-enhanced

SUBMITTER:  

PROVIDER: S-EPMC9354211 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature